The present invention relates to prevention of congenital deformations. The invention further relates to cancer inhibition and prevention. The invention further relates to methods and compositions to modulate, antagonize, or agonize disparate signaling pathways that may converge to regulate patterning events and gene expression during prenatal development, postnatal development, and during development in the adult, organism. The invention also relates to activators or deactivators of pyruvate kinase M2 (PKM2) for the treatment, prevention, or amelioration of diseases related to PKM2 function.

An electrolyte for a lithium secondary battery according to exemplary embodiments of the present inventing includes an organic solvent, a lithium salt, a first additive represented by a predetermined chemical formula, and a second additive represented by a predetermined chemical formula. A protective film is formed by the additives to suppress an expansion of a lithium secondary battery and improve storage property at high temperature.

The present invention relates to prevention of congenital deformations. The invention further relates to cancer inhibition and prevention. The invention further relates to methods and compositions to modulate, antagonize, or agonize disparate signaling pathways that may converge to regulate patterning events and gene expression during prenatal development, post-natal development, and during development in the adult organism. The invention also relates to activators or deactivators of pyruvate kinase M2 (PKM2) for the treatment, prevention, or amelioration of diseases related to PKM2 function.

The present invention relates to prevention of congenital deformations. The invention further relates to cancer inhibition and prevention. The invention further relates to methods and compositions to modulate, antagonize, or agonize disparate signaling pathways that may converge to regulate patterning events and gene expression during prenatal development, post-natal development, and during development in the adult organism. The invention also relates to activators or deactivators of pyruvate kinase M2 (PKM2) for the treatment, prevention, or amelioration of diseases related to PKM2 function.

The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.

The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.

The present invention provides salts of zuclomiphene and crystalline forms thereof. Specific salts of zuclomiphene provided by the present invention include sulphate, phosphate, succinate, L-tartrate, tosylate, L-malate, maleate, malonate, fumarate, glycolate, and hemi-citrate. Also provided are pharmaceutical compositions including the zuclomiphene salts and crystalline forms thereof and the use of these salts in the treatment of a disorder selected from the group including osteoporosis, bone fractures, loss of bone mineral density (BMD) and hot flashes in a subject suffering therefrom.

The silyl phosphine compound is represented by the following general formula (1). A content of a compound represented by the following general formula (2) is not more than 0.3 mol %. In the general formula (1), each R is independently an alkyl group having not less than 1 and not more than 5 carbon atoms or an aryl group having not less than 6 and not more than 10 carbon atoms. In the general formula (2), R is the same as in the general formula (1).

##STR00001##

The present invention relates to a lithium secondary battery including a positive electrode including a positive active material layer, the positive active material layer including a positive active material and a carbonaceous nanostructure; a negative electrode including a negative active material; and an electrolyte. The electrolyte includes a non-aqueous organic solvent, a lithium salt, and an additive including a compound represented by Chemical Formula 1, wherein the amount of the carbonaceous nanostructure is about 0.5 wt % or more and less than 4 wt % based on 100 wt % of the total amount of the positive active material layer. ##STR00001## wherein, in Chemical Formula 1, A is a substituted or unsubstituted aliphatic chain or (—C.sub.2H.sub.4—O—C.sub.2H.sub.4-)n, and n is an integer from 1 to 10.

The present invention relates to a lithium secondary battery including a positive electrode including a positive active material layer, the positive active material layer including a positive active material and a carbonaceous nanostructure; a negative electrode including a negative active material; and an electrolyte. The electrolyte includes a non-aqueous organic solvent, a lithium salt, and an additive including a compound represented by Chemical Formula 1, wherein the amount of the carbonaceous nanostructure is about 0.5 wt % or more and less than 4 wt % based on 100 wt % of the total amount of the positive active material layer. ##STR00001## wherein, in Chemical Formula 1, A is a substituted or unsubstituted aliphatic chain or (—C.sub.2H.sub.4—O—C.sub.2H.sub.4-)n, and n is an integer from 1 to 10.